News | November 13, 2023
Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
Specialty Chemicals grew 38% YoY for FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Subscribe To Our Newsletter & Stay Updated
